Analysis of neutral pions from vµ CC CNGS interactions in the ICARUS detector

The aim of the thesis is the study of the electromagnetic showers and neutral mesons in the ICARUS T600 Liquid Argon Time Projection Chamber. To accurately reconstruct energy of electromagnetic showers, different corrections to the collected charge are needed. In this thesis the author calibrated the energy reconstruction with a set of corrections, most of which are not present in the official ICARUS reconstruction software. For this goal, the simulation package FLUKA was extensively used in order to study the ionization quenching and the shower containment in the detector. As a result the reconstructed invariant ⇡0 masses are distributed compactly (" = 12 MeV/c2) with a best value equal to 134.5 ± 1.5 ± 4.2 MeV/c2. Moreover, other results on low energy electromagnetic showers in Liquid Argon were found which include the longitudinal profile parametrization, the conversion distance measurement and the ionization losses for 1 and 2 m.i.p. particles. This latest point is interesting for the e CC events selection from ⌫μ NC background

The ICARUS T600 Experiment in the Gran Sasso Underground Laboratory

With a mass of about 600 tons of Liquid Argon (LAr), the ICARUS T600 detector is the biggest, up to now, LAr Time Projection Chamber (TPC). Following its successful test run, on the Earth surface, in Pavia (Italy) in 2001, the detector is now very close to start data taking in the Gran Sasso underground laboratory. The main features of the LAr TPC technique, together with a short discussion of some of the ICARUS T600 test run results, are presented in this paper

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Effect of High Temperature on Mechanical Properties of Geopolymer Mortar

The advent of modern aluminosilicate binders has resulted in practical uses for fly ash, which belongs to the group of secondary mineral raw materials; this provides an interesting alternative to cementitious binders, which have a large carbon footprint. Geopolymers mineral binders with a growing range of applications in construction. Their inorganic, amorphous structure endows them with better resistance to high temperature compared to cementitious binders. In this study, the alkaline activation of aluminosilicate Połaniec Fly Ash made it possible to obtain noncementitious material with compressive strength of 18.5 MPa. The article presents the results of a comparison of characteristics of geopolymer mortar and Portland cement mortar after thermal exposure

Compte rendu du « 1er congrès interdisciplinaire du développement durable – Quelle transition pour nos sociétés ?» (Colloque, Namur, Belgique, 31 janvier et 1er février 2013)

info:eu-repo/semantics/publishe